TABLE 1.

Antimicrobial susceptibility to fluoroquinolones and aminoglycosides in P. aeruginosa isolates of animal origin

Country	Year	Animal host	Pathology	No. of isolates	Method	Percentage (%) of resistanced				Reference
						CIP	ENR	GEN	AMI
US.	1998–2003	Dogs/cats	Otitis	319	Sensititre	–e	38.0	15.0	11.0	71
U.S.	1992–2005	Dogs	Pyoderma	20	Disk diffusion	25.0	40.0	5.0	5.0	78
Europea	2008–2010	Dogs	SSTIf	160	Agar dilution	–	16.9	18.8	–	114
		Cats	SSTI	11		–	18.2	9.0	–
Croatia	2007–2009	Dogs	Otitis	104	Etest	8.7	51.9	43.3	–	74
Croatia	1998–2000	Dogs	Otitis	183	Agar dilution	3.8	26.2	10.9	7.6	116
Canada	2003–2006	Dogs	SSTI	106	Sensititre	16.0	31.0	7.0	3.0	73
China	2009–2010	Dogs	SSTI	27	Broth microdilution	14.8	–	14.8	11.1	110
Germany	2004–2006	Dogs/cats	SSTI	71	Broth microdilution	–	24.0	27.0	–	115
			Urinary/genital tract	28		–	11.0	11.0	–
France	2008–2011	Dogs	SSTI	46	Agar dilution	63.0	–	56.5	15.2	124
		Horses	Diverseb	10		0.0	–	10.0	0.0
		Cows	Diversec	12		0.0	–	8.4	0.0
Brazil	2010–2012	Dogs	Otitis, pyoderma	104	Disk diffusion	4.8	26.0	4.8	2.9	113
Japan	2005–2007	Cows	Mastitis	116	Broth microdilution	0.0	31.0	4.3	1.7	154
Japan	Unknown	Chinchillas	Healthy	22		4.5	81.0	0.0	0.0	150
Denmark	2002–2005	Minks	Hemorrhagic pneumonia	39	Sensititre	–	5.1	0.0	–	144
China	2010–2011	Minks	Hemorrhagic pneumonia	30	VITEK-2	13.3	–	0.0	0.0	146

^a Czech Republic, France, Germany, Hungary, Italy, the Netherlands, Poland, Spain, Sweden, and the United Kingdom.

^b Respiratory infections, skin or eye infections, metritis.

^c Mastitis, digestive and respiratory infections.

^d CIP, ciprofloxacin; ENR, enrofloxacin; GEN, gentamicin; AMI, amikacin.

^e –, Not performed.

^f SSTI, Skin and Soft Tissues Infections.